{"prompt": "['Novartis', 'Confidential', 'Page 66', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '16', 'Appendices', '16.1', 'Appendix 1: Clinically notable laboratory values and vital signs', 'The central laboratory will flag laboratory values falling outside of the normal ranges on the', 'central laboratory reports. Investigators are responsible for reviewing these abnormal values for', 'clinical significance, signing the laboratory reports to indicate their review, and reporting values', 'considered clinically significant in the appropriate electronic case report form (eCRF).', 'Any clinically significant abnormal laboratory value should be evaluated and followed-up by', 'the Investigator until normal or a cause for the abnormality is determined.', 'See Section 16.2 for specific liver event and laboratory test trigger definitions and follow-', 'up requirements. See Section 16.3 for specific renal alert criteria and actions.', 'For electrocardiograms (ECGs), a notable QTc value is defined as a QTcF (Fridericia) interval', 'of>450 msec for males or >460 msec for females. All ECGs will be assessed locally at site and', 'with assessment of clinical relevance and continuance of the patient being confirmed by the', 'Investigator.']['Novartis', 'Confidential', 'Page 67', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '16.2', 'Appendix 2: Liver event and Laboratory trigger Definitions and', 'Follow-up Requirements', 'Table 16-1', 'Liver Event and Laboratory Trigger Definitions', 'Definition/ threshold', 'LIVER LABORATORY', '3 X ULN < ALT / AST 5 X ULN', 'TRIGGERS', '1.5 X ULN < TBL 2 X ULN', 'LIVER EVENTS', 'ALT or AST > 5 x ULN', 'ALP > 2 x ULN (in the absence of known bone pathology)', 'TBL > 2 x ULN (in the absence of known Gilbert syndrome)', 'ALT or AST > 3 x ULN and INR > 1.5', \"Potential Hy's Law cases (defined as ALT or AST > 3 x ULN and TBL > 2\", 'x', 'ULN [mainly conjugated fraction] without notable increase in ALP to > 2 x', 'ULN)', 'Any clinical event of jaundice (or equivalent term)', 'ALT or AST > 3 x ULN accompanied by (general) malaise, fatigue, abdominal', 'pain, nausea, or vomiting, or rash with eosinophilia', 'Any adverse event potentially indicative of a liver toxicity*', '*', 'These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related', 'conditions; the non-infectious hepatitis; the benign, malignant and unspecified liver neoplasms TBL=total', 'bilirubin; ULN=upper limit of normal', 'Table 16-2', 'Follow Up Requirements for Liver Events and Laboratory Triggers', 'Criteria', 'Actions required', 'Follow-up monitoring', \"Potential Hy's Law casea\", 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb,', 'Hospitalize, if clinically appropriate', 'PT/INR, ALP and yGT', 'until resolution', 'Establish causality', '(frequency at Investigator', 'Record the AE and contributing factors (e.g.,', 'discretion)', 'conmeds, med hx, lab) in the appropriate CRF', 'ALT or AST', '> 8 x ULN', 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb,', 'Hospitalize if clinically appropriate', 'PT/INR, ALP and yGT', 'until resolution\u00b0', 'Establish causality', '(frequency at Investigator', 'Record the AE and contributing factors (e.g.,', 'discretion)', 'conmeds, med hx, lab) in the appropriate CRF', '> 3 x ULN and INR > 1.5', 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb,', 'Hospitalize, if clinically appropriate', 'PT/INR, ALP and yGT', 'until resolution', 'Establish causality', '(frequency at Investigator', 'Record the AE and contributing factors (e.g.,', 'discretion)', 'conmeds, med hx, lab) in the appropriate CRF', '> 5 to 8 x ULN', 'Repeat LFT within 48 hours', 'ALT, AST, TBL, Alb,', 'If elevation persists, continue follow-up', 'PT/INR, ALP and yGT', 'monitoring', 'until resolution', '(frequency at Investigator', 'If elevation persists for more than 2 weeks,', 'discretion)', 'discontinue the study drug', 'Establish causality', 'Record the AE and contributing factors (e.g.,', 'conmeds, med hx, lab) in the appropriate CRF']['Novartis', 'Confidential', 'Page 68', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Criteria', 'Actions required', 'Follow-up monitoring', '> 3 x ULN accompanied by', 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb,', 'symptomsb', 'Hospitalize if clinically appropriate', 'PT/INR, ALP and yGT', 'until resolution', 'Establish causality', '(frequency at Investigator', 'Record the AE and contributing factors (e.g.,', 'discretion)', 'conmeds, med hx, lab) in the appropriate CRF', '> 3 to 5 x ULN (patient is', 'Repeat LFT within the next week', 'Investigator discretion', 'asymptomatic)', 'If elevation is confirmed, initiate close', 'Monitor LFT within 1 to 4', 'observation of the patient', 'weeks', 'ALP (isolated)', '> 2 x ULN (in the absence', 'Repeat LFT within 48 hours', 'Investigator discretion', 'of known bone pathology)', 'If elevation persists, establish causality', 'Monitor LFT within 1 to 4', 'Record the AE and contributing factors (e.g.,', 'weeks or at next visit', 'conmeds, med hx, lab) in the appropriate CRF', 'TBL (isolated)', '> 2 x ULN (in the absence', 'Repeat LFT within 48 hours', 'ALT, AST, TBL, Alb,', 'of known Gilbert', 'If elevation persists, discontinue the study drug', 'PT/INR, ALP and yGT', 'syndrome)', 'immediately', 'until resolution', '(frequency at Investigator', 'Hospitalize if clinically appropriate', 'discretion)', 'Establish causality', 'Test for hemolysis (e.g.,', 'Record the AE and contributing factors (e.g.,', 'reticulocytes,', 'conmeds, med hx, lab) in the appropriate CRF', 'haptoglobin,', 'unconjugated [indirect]', 'bilirubin)', '> 1.5 to 2 x ULN (patient', 'Repeat LFT within the next week', 'Investigator discretion', 'is asymptomatic)', 'If elevation is confirmed, initiate close', 'Monitor LFT within 1 to 4', 'observation of the patient', 'weeks or at next visit', 'Jaundice', 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb,', 'Hospitalize the patient', 'PT/INR, ALP and yGT', 'until resolution', 'Establish causality', '(frequency at Investigator', 'Record the AE and contributing factors (e.g.,', 'discretion)', 'conmeds, med hx, lab) in the appropriate CRF', 'Any AE potentially', 'Consider study treatment interruption or', 'Investigator discretion', 'indicative of a liver toxicity', 'discontinuation', 'Hospitalization if clinically appropriate', 'Establish causality', 'Record the AE and contributing factors (e.g.,', 'conmeds, med hx, lab) in the appropriate CRF', 'Elevated ALT/AST > 3 x ULN and TBL > 2 x ULN but without notable increase in ALP to > 2 x ULN (General)', 'malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia Resolution is defined as an', 'outcome of one of the following: (1) return to baseline values, (2) stable values at three subsequent monitoring', 'visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6 months, (4) liver transplantation,', 'and (5) death.']\n\n###\n\n", "completion": "END"}